NO983946L - Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner - Google Patents

Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner

Info

Publication number
NO983946L
NO983946L NO983946A NO983946A NO983946L NO 983946 L NO983946 L NO 983946L NO 983946 A NO983946 A NO 983946A NO 983946 A NO983946 A NO 983946A NO 983946 L NO983946 L NO 983946L
Authority
NO
Norway
Prior art keywords
vaccines
preparation
foreign dna
containing foreign
viruses containing
Prior art date
Application number
NO983946A
Other languages
English (en)
Norwegian (no)
Other versions
NO983946D0 (no
Inventor
Norbert Schmeer
Walter Strube
Ttner Mathias B
Hans-Joachim Rziha
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19639601A external-priority patent/DE19639601A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO983946D0 publication Critical patent/NO983946D0/no
Publication of NO983946L publication Critical patent/NO983946L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO983946A 1996-02-28 1998-08-27 Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner NO983946L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19607458 1996-02-28
DE19639601A DE19639601A1 (de) 1996-02-28 1996-09-26 Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
PCT/EP1997/000729 WO1997032029A1 (fr) 1996-02-28 1997-02-17 Parapoxvirus contenant de l'adn etranger, leur production et leur utilisation dans des vaccins

Publications (2)

Publication Number Publication Date
NO983946D0 NO983946D0 (no) 1998-08-27
NO983946L true NO983946L (no) 1998-10-22

Family

ID=26023280

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983946A NO983946L (no) 1996-02-28 1998-08-27 Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner

Country Status (19)

Country Link
US (1) US6365393B1 (fr)
EP (1) EP0886679B1 (fr)
JP (1) JP2000507092A (fr)
CN (1) CN1217027A (fr)
AT (1) ATE364090T1 (fr)
AU (1) AU718141B2 (fr)
BR (1) BR9707785A (fr)
CA (1) CA2247336C (fr)
DE (1) DE59712852D1 (fr)
DK (1) DK0886679T3 (fr)
ES (1) ES2287949T3 (fr)
HU (1) HUP9901035A3 (fr)
IL (1) IL125797A0 (fr)
NO (1) NO983946L (fr)
NZ (1) NZ331556A (fr)
PL (1) PL190401B1 (fr)
SK (1) SK120098A3 (fr)
TR (1) TR199801702T2 (fr)
WO (1) WO1997032029A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0904393A4 (fr) * 1996-03-29 1999-09-08 Univ Otago Vecteurs de parapoxvirus
PT2016951E (pt) * 1998-03-17 2012-09-27 Genentech Inc Polipéptidos homólogos de vegf e de bmp1
DE69931178T8 (de) * 1998-11-02 2007-06-28 Ludwig Institute For Cancer Research Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
CA2415397C (fr) * 2000-07-11 2011-04-26 Bayer Aktiengesellschaft Utilisation de souches de parapoxvirus ovis pour la production de medicaments antiviraux et de medicaments anticancereux
EP1499355A4 (fr) 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp Utilisation d'une proteine b2l de parapox pour traiter le cancer et modifier des reponses immunitaires
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
ATE442155T1 (de) * 2004-07-13 2009-09-15 Aicuris Gmbh & Co Kg Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids
KR20130058706A (ko) 2010-04-29 2013-06-04 림사 아르쯔나이미텔 아게 토끼 출혈병 바이러스의 ｖｐ６０ 주요 캡시드 단백질을 발현하는 파라폭스바이러스
AU2011254315B2 (en) 2010-05-21 2015-05-14 Zoetis Services Llc Parapoxvirus vectors containing rabies virus antigen
RU2013102413A (ru) * 2010-07-20 2014-08-27 ЭйЭйч ЮЭсЭй 42 ЭлЭлСи Парапоксвирусные векторы
WO2014015091A2 (fr) 2012-07-19 2014-01-23 Zoetis Llc Compositions de virus de la grippe bovine
WO2014018724A1 (fr) 2012-07-27 2014-01-30 Zoetis Llc Compositions de toxine de tique
DE102015111756A1 (de) 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
AU2016307935B2 (en) 2015-08-14 2022-08-18 The University Of Melbourne Mycoplasma bovis compositions
US11013798B2 (en) 2016-03-21 2021-05-25 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
BR112020018117A2 (pt) 2018-03-07 2020-12-22 Transgene Vírus da pseudovaríola (pcpv), métodos para gerar o pcpv e para amplificar o pcpv, composição, método de tratamento, método para inibir o crescimento de células tumorais, uso ou método e método para induzir ou estimular e/ ou reorientar uma resposta imune
WO2024062098A1 (fr) 2022-09-23 2024-03-28 Transgene Virus de la paraviccine recombinant codant pour l'interleukine-12

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE298370T1 (de) * 1994-04-29 2005-07-15 Baxter Healthcare Sa Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen

Also Published As

Publication number Publication date
IL125797A0 (en) 1999-04-11
PL328870A1 (en) 1999-03-01
ATE364090T1 (de) 2007-06-15
NZ331556A (en) 2000-05-26
HUP9901035A2 (hu) 1999-07-28
SK120098A3 (en) 1999-03-12
CA2247336A1 (fr) 1997-09-04
DE59712852D1 (de) 2007-07-19
EP0886679B1 (fr) 2007-06-06
DK0886679T3 (da) 2007-09-24
JP2000507092A (ja) 2000-06-13
US6365393B1 (en) 2002-04-02
NO983946D0 (no) 1998-08-27
BR9707785A (pt) 1999-07-27
WO1997032029A1 (fr) 1997-09-04
PL190401B1 (pl) 2005-12-30
AU718141B2 (en) 2000-04-06
AU1725797A (en) 1997-09-16
HUP9901035A3 (en) 2001-01-29
TR199801702T2 (xx) 1998-12-21
ES2287949T3 (es) 2007-12-16
EP0886679A1 (fr) 1998-12-30
CA2247336C (fr) 2008-06-17
CN1217027A (zh) 1999-05-19

Similar Documents

Publication Publication Date Title
NO983946L (no) Parapoxviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
ATE404220T1 (de) Rekombinierte pockenvirus-tollwut zusammensetzung und kombinierte zusammensetzungen und deren verwendung
DE69830579D1 (de) Chimäre impfstoffe gegen flaviviren
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
NO20013701L (no) HER-2/neu-fusjonsproteiner
SI1554301T1 (sl) VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE
ATE328068T1 (de) Papillomavirus vakzine
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
ATE286067T1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
IL181695A0 (en) Methods for cultivating cells and propagating viruses
DE69836520D1 (de) Clostridium perfringens Impfstoff
YU36698A (sh) Parapoks-virusi koji sadrže stranu dnk, njihovo dobijanje i njihova primena u vakcinama
EP0868522A4 (fr) Virus de recombinaison combine de la variole et de la peritonite infectieuse du chat, compositions le contenant et leurs procedes d'obtention et d'utilisation
DK0704501T3 (da) Højtransparente, røde jernoxidpigmenter, fremgangsmåde til deres fremstilling og anvendelse
DE69840637D1 (de) Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
DK0831899T3 (da) Rekombinant koppevirus-calicivirus-præparater og anvendelser
FI971275A7 (fi) Inaktivoidun IVa2-geenin käsittävät epätäydelliset yhdistelmä-DNA-tekn iset adenovirukset
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
WO1998024912A3 (fr) Vaccin contre la peste obtenu par recombinaison
BR9915970A (pt) Vìrus recombinante expressando dna exógenocodificando cd80 felino, ctla-4 felino ou cd86 felinoe usos do mesmo
NZ511168A (en) Recombinant CELO virus and CELO virus DNA
FI964784L (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
NZ330913A (en) Antigens for preventing and reducing parasite infection and disease
ATE132527T1 (de) Nicht-zurückmutierende rna-viren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application